[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adherence-medication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adherence-medication":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,56,86,115,151,174,200,229,252,277,301],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":40,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100638424","ecardiacrehab---a-hybrid-patient-centered-ehealth-programme-100638424",false,"NCT07590635","eCardiacRehab - a Hybrid Patient-Centered eHealth Programme","eCardiacRehab - a Randomized Controlled Trial on a Hybrid Home-Based Patient-Centered eHealth Programme With Tailored Solutions","eCardiacRehab","Inclusion Criteria:\n\n* Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number\n* With coronary artery disease after percutaneous coronary intervention\n* Living at home\n* Have internet available\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Patients with cognitive impairment that may interfere with the ability to comply with the study protocol\n* Severe aortic stenosis\n* Severe arrhythmias\n* Expected lifetime less than one year as determined by study personnel\n* Otherwise clinically unstable\n* Not fully revascularized\n* Awaits percutaneous coronary intervention or coronary artery bypass graft surgery\n* Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all.\n\neCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Comorbidities and Coexisting Conditions","Ethics","Continuity of Patient Care","Older Adults (65 Years and Older)","Cost-Benefit Analysis","Adherence, Medication","Secondary Prevention of Coronary Heart Disease","Health Literacy","eHealth Literacy","Mental Health","Cardiac Rehabilitation","Womens's Health","Coronary Artery Disease (CAD)",[37,41,42],"Coronary Artery Disease","Percutaneous Coronary Intervention","RECRUITING","2026-06-18",{"date":46,"type":47},"2026-06-23","ACTUAL",{"date":49,"type":47},"2026-05-21",{"date":51,"type":21},"2037-12-31",{"name":53,"class":54},"Haukeland University Hospital","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":55},"100639018","phase-4-adherence-and-safety-of-ribociclib-plus-aromatase-inhibitors-in-patients-with-early-stage-hr-and-her2--breast-cancer-100639018","NCT07630948","Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer","Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, Hormonal Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","riboADHERE","Inclusion Criteria:\n\n* Female or male patient prescribed with ribociclib in combination with an aromatase inhibitor independently of trial participation\n* Patient was prescribed ribociclib independently of this trial protocol and has not yet started cycle 1\n* Patient is ≥ 18 years-old at the time of ICF signature\n* Patient has mandatory Slovenian health insurance\n* Patient understands and speaks Slovenian language and is of congitive capability to participate in the trial\n* Patient has access to phone\n* Patient voluntarily agrees to participate in the trial and provides written ICF\n\nExclusion Criteria:\n\n* Patient is not treated with the combination of ribociclib and aromatase inhibitor for Early BC\n* Metastatic Hormone Receptor positive and HER2- negative BC\n* Any medical condition that, in the opinion of the investigator, would interfere with adherence participation in the trial (i.e. significant cognitive impairment, psychiatric condition)\n* Language barrier that precludes informed consent or meaningful participation in the adherence intervention",{"count":65,"type":21},90,[67],"PHASE4","Breast cancer is the most common malignancy in women, with HR+\u002FHER2- early breast cancer accounting for approximately 70% of cases. Although adjuvant endocrine therapy substantially reduces the risk of recurrence, a clinically meaningful proportion of patients, particularly those with intermediate- and high-risk disease, still experience relapse. The addition of CDK4\u002F6 inhibitors such as ribociclib to endocrine therapy has demonstrated significant improvement in invasive disease-free survival (iDFS) and is now part of standard adjuvant treatment for selected patients. However, the real-world effectiveness of prolonged oral therapy depends heavily on patient adherence, which may be negatively affected by treatment duration, adverse events, and the absence of immediate perceived benefit. Evidence regarding adherence to adjuvant ribociclib therapy in routine clinical practice remains limited. This study therefore aims to evaluate whether a structured adherence-support intervention can improve treatment adherence during ribociclib therapy and to explore the relationship between adherence and long-term clinical outcomes, including iDFS.",[70,32],"Breast Cancer",[72,73,74,75],"HR+","HER2-","Early breast cancer","CDK4\u002F6 adherence","NOT_YET_RECRUITING","2026-06-03",{"date":79,"type":47},"2026-06-05",{"date":81,"type":21},"2026-09-01",{"date":83,"type":21},"2032-09-01",{"name":85,"class":54},"Institute of Oncology Ljubljana",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100634950","peer-led-service-delivery-model-for-pregnant-and-lactating-adolescent-girls-and-young-women-in-zimbabwe-100634950","NCT07546344","Peer-led Service Delivery Model for Pregnant and Lactating Adolescent Girls and Young Women in Zimbabwe","Peer-led Service Delivery Model to Increase HIV Prevention and Contraception in Pregnant and Lactating Adolescent Girls and Young Women in Zimbabwe: a Pilot Study","Ontanga","Inclusion Criteria:\n\n* either pregnant or have at least one child who is less than 18 months of age at the time of initial engagement\n* Aged 15 - 24 years old",true,"FEMALE","15 Years","24 Years",{"count":99,"type":21},600,[24],"This is a pilot cluster-randomized control trial co-led by Dr. Valentina Cambiano, Associate Professor of Epidemiology at University College London, UK and Professor Euphemia Sibanda, Research Director at the Centre for Sexual Health and HIV Research (CeSHHAR Zimbabwe). The goal of the proposed study is to evaluate the appropriateness, feasibility, acceptability, uptake, costs and cost-effectiveness of a community-based, HIV-status neutral peer-led service delivery model in which young mentor mothers (YMM) work with pregnant and lactating adolescent girls and young women (PL-AGYW, aged 15-24), up to two-years post-birth, in Zimbabwe to promote uptake of contraception and HIV prevention.\n\nYMM living with HIV have been found to be effective in supporting their peers for prevention of mother-to-child transmission of HIV and adherence to treatment through the \"Zvandiri\" programme. The investigators propose adapting the \"Zvandiri\" YMM to include those without HIV to promote behaviour to prevent HIV and unintended pregnancies. This proposed intervention is building on the formative work that had the overall aim of co-developing with AGYW (aged 15-24) a Pre-Exposure Prophylaxis (PrEP) implementation intervention for AGYW who need it, that attracts them to PrEP, and supports pregnant and lactating adolescent girls and young women while taking it.",[103,104,32],"HIV Prevention","Contraceptive Usage","2026-04-16",{"date":107,"type":47},"2026-04-22",{"date":109,"type":21},"2026-04",{"date":111,"type":21},"2027-06",{"name":113,"class":54},"University College, London",3,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":55},"100486356","leveraging-technology-to-improve-medication-adherence-in-youth-with-kidney-or-liver-transplant-100486356","NCT05613010","Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant","Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial","Inclusion Criteria:\n\n* Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment\n* Currently prescribed tacrolimus or sirolimus.\n\nExclusion Criteria:\n\n* Currently receiving dialysis\n* Hospitalized for duration of study\n* Significant developmental or cognitive delay\n* No access to a mobile device that supports text messaging\n* Decline to use electronic pill box to monitor daily medication adherence\n* Non-English speaking\n* If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.","13 Years","25 Years",{"count":125,"type":21},65,[24],"Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.",[129,130,32,131,132],"Transplant;Failure,Kidney","Transplant; Failure, Liver","Adherence, Patient","Adherence, Treatment",[134,135,136,137,138,139,140,141],"kidney transplant","liver transplant","medication adherence","medication nonadherence","compliance","mobile health","mobile phone","technology","2026-04-09",{"date":144,"type":47},"2026-04-13",{"date":146,"type":47},"2024-03-19",{"date":148,"type":21},"2026-11-30",{"name":150,"class":54},"Johns Hopkins University",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100631809","early-phase-1-visualization-of-the-effects-of-guideline-directed-medical-therapy-gdmt-on-improving-adherence-and-quality-of-life-in-heart-failure-with-reduced-ejection-fraction-hfref-100631809","NCT07505511","Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)","VISUALIZE-PRO","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction ≤40%)\n* Indication for guideline-directed medical therapy (GDMT) for heart failure\n* Stable clinical condition at the time of enrollment\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Acute decompensated heart failure requiring immediate hospitalization\n* Severe cognitive impairment or inability to understand study-related information\n* Life expectancy \\\u003C6 months due to non-cardiac comorbidities\n* Participation in another interventional clinical trial that may interfere with this study\n* Contraindications to prescribed heart failure medications\n* Any condition that, in the investigator's judgment, precludes safe participation in the study",{"count":159,"type":21},100,[161],"EARLY_PHASE1","Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge with substantial morbidity and mortality despite the availability of effective guideline-directed medical therapy (GDMT). Although four major drug classes have been shown to significantly improve survival and reduce hospitalizations, real-world implementation remains suboptimal. In addition to underutilization by healthcare providers, poor medication adherence among patients-reported to range between 29% and 63%-represents a critical barrier to achieving optimal therapeutic benefit.\n\nThe Visualize-Pro study is a prospective, exploratory pilot study designed to evaluate a simple, patient-centered intervention aimed at improving medication adherence in patients with HFrEF. The intervention consists of patient-friendly graphical visualizations illustrating the survival benefits and risk reduction associated with optimal heart failure therapy. These materials are designed to enhance patient understanding, motivation, and engagement with prescribed treatments.\n\nTo objectively assess medication adherence, this study incorporates therapeutic drug monitoring (TDM) as a gold standard method, in addition to established patient-reported outcome measures such as quality of life and adherence questionnaires. Blood samples will be collected at predefined study visits, and drug levels (or their metabolites) will be analyzed in collaboration with a specialized laboratory to quantify adherence.\n\nParticipants will be followed over a predefined study period with serial assessments at scheduled visits.\n\nThe primary objective is to evaluate the feasibility and preliminary effectiveness of the intervention in improving medication adherence. Secondary objectives include assessing changes in patient-reported outcomes and exploring associations between adherence and clinical parameters.\n\nAs a pilot study, the results are intended to inform the design of a future large-scale, multicenter trial. Ultimately, this approach aims to provide a scalable and low-threshold strategy to improve adherence to life-saving therapies in heart failure, thereby contributing to reduced morbidity and mortality in this high-risk population.",[32,132,164],"Heart Failure","2026-03-29",{"date":167,"type":47},"2026-04-01",{"date":169,"type":21},"2026-03-01",{"date":171,"type":21},"2028-03-01",{"name":173,"class":54},"University of Giessen",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":188,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":55},"100481279","mobile-health-program-for-rural-hypertension-100481279","NCT05546931","Mobile Health Program for Rural Hypertension","Multilevel Mobile Health Program to Improve Rural Hypertension","Inclusion Criteria:\n\n1. History of uncontrolled hypertension, identified from the electronic health record problem list and an average systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits, one of which is within 6 months of study entry\n2. Residence in one of 48 counties categorized as rural by the Center for Rural Pennsylvania;\n3. English-speaking at level appropriate for informed consent and study participation;\n4. No plans to relocate from the area within 12 months of enrollment.\n\nExclusion Criteria:\n\n1. Heart failure necessitating hospital admission ≤3 months prior to study inclusion;\n2. Acute coronary syndrome (defined as at least 2 of the following: chest pain, ischemic electrocardiographic changes, or troponin ≥0.1 ng\u002FmL) ≤3 months prior to study inclusion;\n3. Planned major surgery, cardiovascular or non-cardiovascular;\n4. Pregnancy or planned pregnancy within 12 months;\n5. Presence of non-cardiovascular conditions likely to be fatal within 12 months (e.g., cancer);\n6. Inability to comprehend the study protocol, defined by failing 3 times to answer correctly a set of questions during consent;\n7. Institutionalized status (e.g., nursing home, incarceration);\n8. Inability to operate a smartphone or HBPM device due to sensory or neurocognitive deficit.",{"count":182,"type":21},334,[24],"Hypertension (HTN) is the leading modifiable cause of cardiovascular disease. Rural individuals experience challenges of the rural health divide: geographic distance from providers, social isolation, limited social resources, and high rates of low health literacy. This study evaluates a home-based blood pressure monitoring (HBPM) program that provides longitudinal health education, empathic guidance, monitoring, and adaptable patient-centered coaching to rural individuals. Participants in this study will be randomized to receive (1) HBPM with the intervention; or (2) the control, consisting of HBPM and a smartphone with a general health application (WebMD).",[186,32,187],"Hypertension,Essential","Quality of Life",[189,190,191],"hypertension","adherence","rurality","2025-11-16",{"date":194,"type":47},"2025-11-19",{"date":196,"type":47},"2023-09-04",{"date":111,"type":21},{"name":199,"class":54},"University of Pittsburgh",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":18,"maxAge":97,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":55},"100520397","making-art-work-among-brazilian-youth-100520397","NCT06056037","Making ART Work Among Brazilian Youth","Making Universal, Free-of-charge Antiretroviral Therapy Work for Sexual and Gender Minority Youth in Brazil","Inclusion Criteria:\n\n* between 18 and 24 years of age\n* assigned male sex at birth\n* identify as a gay or bisexual man, or a transgender woman or another gender identity along the feminine spectrum\n* self-report living with HIV, and verified by medical chart review,\n* self-report currently taking or prescribed ART for \\> 3 months\n* self-report missing 2 or more doses of ART medications in any given week in the past month OR not virally suppressed (i.e., \\>40 copies\u002FmL in past 3 months; via national outpatient data \\[SISCEL\\] or plasma viral load testing)\n* owns a cell phone or willing to use one as part of the study\n\nExclusion Criteria:\n\n* unable to give informed consent due to cognitive limitation, severe mental\u002Fphysical illness or intoxication\n* unable to read and\u002For write to an extent that would limit their ability to comprehend the informed consent\n* lived in the greater Rio de Janeiro area for \\\u003C 3 months or planning to move outside the area within the next year","MALE",{"count":209,"type":21},72,[24],"This study seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among sexual and gender minority (SGM) young people living with HIV (ages 18-24) in Rio de Janeiro, Brazil. The intervention aims to improve social support, self-efficacy for taking ART, and teach skills for problem-solving barriers to promote better adherence.",[213,32],"Hiv",[215,216,217,218,219],"Brazil","sexual and gender minority","adolescents","HIV","Medication adherence","2025-09-15",{"date":222,"type":47},"2025-09-19",{"date":224,"type":47},"2023-10-01",{"date":226,"type":21},"2026-04-30",{"name":228,"class":54},"Brown University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":55},"100477340","triple-therapy-convenience-by-the-use-of-one-or-multiple-inhalers-and-digital-support-in-chronic-obstructive-pulmonary-disease-100477340","NCT05495698","Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease","TRICOLON","Inclusion Criteria:\n\n* Clinical diagnosis of COPD for at least 1 year before the screening visit\n* Aged 40 years and older\n* An indication for triple therapy according to the treating physician (following the GOLD guideline 2021(2)). Could be step-up from dual therapy or currently receiving triple therapy (both MITT and SITT).\n* Owner of mobile device compatible with e-device app with access to internet (Android or iOS)\n* Willing to provide written informed consent\n* Current or ex-smoker\n\nExclusion Criteria:\n\n* Inability to comply with study procedures or with study treatment\n* Insufficiently skilled in the Dutch language to be able to read and understand the app. Help by third party (family members) is allowed\n* Asthma as the predominant disease according to the investigator's opinion, a past history of asthma is allowed\n* Use of e-health application for COPD in the past six months\n* Patients with any other therapy that could interfere with the study drugs (according to the investigator's opinion)\n* Use of nebulized bronchodilators, for example via pari boy\n* Pregnant or lactating women and all women physiologically capable of becoming pregnant unless they have highly effective contraceptive\n* Patients mentally or legally incapacitated, or patients accommodated in an establishment as a result of an official or judicial order\n* Patients without the capability to complete the questionnaires","40 Years",{"count":238,"type":21},300,[24],"TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.",[242,32],"Copd","2025-08-20",{"date":245,"type":47},"2025-08-21",{"date":247,"type":47},"2022-12-13",{"date":249,"type":21},"2026-12",{"name":251,"class":54},"Franciscus Gasthuis",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":236,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":55},"100494970","role-of-coronary-cta-on-lipid-management-and-risk-factors-control-in-an-asymptomatic-chinese-population-100494970","NCT05725096","Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population","Role of the Screening with Coronary Computed Tomography Angiography on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population: a Community-based, Prospective Randomised Trial","RESPECT2","Inclusion Criteria:\n\n1. Nanjing residents who have no plans to leave in the next 5 years\n2. Aged from 40 to 69 years\n3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form\n\nExclusion Criteria:\n\n1. Serious liver dysfunction, defined as AST or ALT \\> 3 times the normal upper limit\n2. Chronic kidney disease (CKD) \\> stage 4, defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n3. Prior CCTA or invasive coronary angiography within the last 5 years\n4. Any contraindications for CCTA\n5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)\n6. Life expectancy \\\u003C 3 years\n7. Other reasons the researcher deems inappropriate to attend","69 Years",{"count":262,"type":21},3400,[24],"The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.",[266,267,268,32],"Statin","Cardiovascular Risk Factors","Primary Prevention","2024-11-25",{"date":271,"type":47},"2024-11-26",{"date":273,"type":47},"2023-06-28",{"date":111,"type":21},{"name":276,"class":54},"Zhang longjiang,MD",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":94,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":55},"100558414","phase-3-testing-a-real-time-electronic-antiretroviral-adherence-monitoring-intervention-100558414","NCT06550804","Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention","Pilot Trial of a Real-time Electronic Adherence Monitoring Intervention for Antiretroviral Therapy","A-TEAM","Inclusion Criteria:\n\nParticipant inclusion criteria:\n\n* AAMSM \\>18 years with self-reported HIV infection;\n* own a working cell phone;\n* on ART for at least 6 months;\n* have a case manager willing to participate in the study (for the clinical trial); and\n* have suboptimal adherence - either have a detectable viral load in the past 6 months, self-reported \\\u003C90% adherence based on a 3-item measure or referral by their healthcare provider because of a recognized problem with ART adherence.\n\nFor social support persons, participants will:\n\n* report that they have a self-described meaningful relationship with the participant;\n* be \\>18 years of age;\n* own a working cell phone and;\n* be willing to provide support.\n\nFor case managers, participants will have worked with clients with HIV at least 6 months prior to their participation in this study and own a working cell phone.\n\nExclusion Criteria:\n\n* Not meeting the inclusion criteria\n* Not agreeing to informed consent concerning interactions with research team, data collection, and access to medical records.\n* Candidates must provide consent to obtain a copy of their viral load results during the 12 months before and following study onset to confirm eligibility and explore long-term follow-up of possible effect.",{"count":286,"type":21},126,[288],"PHASE3","The investigators propose using an electronic adherence device that is basically a pill container that can alert when it is not opened at a scheduled time. The investigators will use this device to alert the medication user at the time when medication is supposed to be taken if the device did not get opened and a pre-identified social support person or case manager when 2 or 7 consecutive days of nonadherence are detected, respectively. The investigators call our approach \"A-Team\" (Antiretroviral Therapy Electronic Adherence Monitoring). The aims of this application are to determine the acceptability and feasibility of real-time adherence monitoring in support persons and case managers of African American Men who have sex with Men and to test this approach for these men in a 6-month randomized controlled trial among 54 of these men living with HIV and measure ART adherence and viral suppression (the primary outcome).",[291,32],"HIV Infections","2024-11-18",{"date":294,"type":47},"2024-11-21",{"date":296,"type":47},"2024-10-01",{"date":298,"type":21},"2026-07",{"name":300,"class":54},"University of Illinois at Chicago",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":94,"sex":95,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":326,"locationsCount":55},"100530092","transmaculine-one-on-one-and-group-empowerment-for-targeted-hiv-reduction-100530092","NCT06182280","Transmaculine One-on-One and Group Empowerment for Targeted HIV Reduction","Strategies to Prevent HIV Acquisition Among Transgender Men Who Have Sex With Men (TMSM)","TOGETHR","Inclusion Criteria:\n\n* Age 18 or over\n* Assigned female sex at birth\n* Identifies as a man, trans man, or another transmasculine identity\n* Has had sex with a partner assigned male sex at birth with a flesh penis in the last 3 months\n* Has access to a smartphone or computer with internet access\n* Is HIV-uninfected\n* Resides in one of the Ending the Epidemic targeted geographic hotspots in the United States\n* Willing and able to provide informed consent in English\n* Meets CDC guidelines for PrEP indications in the last 3 months (adapted for TMSM) including:\n* Condomless receptive vaginal\u002Ffrontal or anal sex with a partner assigned male at birth with a flesh penis\n* Sharing needles or syringes for illicit drug use and\u002For hormones\n* Self-reported anogenital sexually transmitted infection diagnosis\n\nExclusion Criteria:\n\n* Less than age 18\n* Not assigned female sex at birth\n* Does not identify as a man, trans man, or another transmasculine identity\n* Does not have access to a smartphone or computer\n* Is living with HIV (HIV positive)\n* Does not reside in one of the Ending the Epidemic geographic hotspots in the United States\n* Will not or cannot provide written informed consent in English\n* Does not meet the trans-adapted CDC guidelines for PrEP indications",{"count":310,"type":21},375,[24],"Transgender masculine and gender diverse people who have sex with men (TMSM) have an increased risk of HIV and face unique barriers engaging in prevention services. Digitally delivered support interventions addressing HIV prevention barriers delivered by peers in one-on-one or small-group settings may be effective at increasing PrEP engagement. This study examines the independent and combined effects of individual and group-based peer-support interventions on PrEP outcomes. Participants will be randomly assigned to receive: (i) standard-of-care HIV prevention information, (ii) a one-on-one healthy lifestyle intervention tailored for transgender masculine people, (iii) a peer-group based healthy lifestyle intervention for transgender masculine people, or (iv) both the one-on-one and group-based interventions delivered together. The hypotheses are that the individual group-based interventions will result in higher PrEP uptake and persistence than the standard of care and that the combined interventions will be more effective than receiving one individual intervention.",[291,32],[315,316,317,318,319],"Transgender","Men who have sex with men","pre-exposure prophylaxis","behavioral intervention","HIV prevention","2023-12-13",{"date":322,"type":47},"2023-12-26",{"date":324,"type":21},"2024-01",{"date":111,"type":21},{"name":327,"class":54},"Fenway Community Health"]